Tech Company Financing Transactions
OnKure Funding Round
OnKure secured a $7 million Series A venture capital round on 5/3/2018. Investors included Delian Capital and private investors.
Transaction Overview
Company Name
Announced On
5/3/2018
Transaction Type
Venture Equity
Amount
$7,000,000
Round
Series A
Investors
Delian Capital (Lead Investor) (Guobao Zhao)
Proceeds Purpose
The investment will help the company aggressively accelerate its research and development activities.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1105 Spruce St.
Boulder, CO 80302
USA
Boulder, CO 80302
USA
Phone
Website
Email Address
Overview
OnKure is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that include selective inhibitors of histone deacetylases (HDACs).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Anthony Piscopio
Chief Financial Officer
Michael Carruthers
Chief Medical Officer
Gail Eckhardt
Chief Operating Officer
John DeMattei
Chief Scientific Officer
Xuedong Liu
Vice President
James Winkler
VP - General Counsel
Keith Olivia
Browse more venture capital transactions:
Prev: 5/3/2018: Upbound venture capital transaction
Next: 5/3/2018: StorageOS venture capital transaction
Share this article
Where The Data Comes From
We document all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs